Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
GHK-Cu
Skin & Hair Health
Molecular Dossier
- Rank Index: 8
- Status: FDA Category 1
- What does this mean?
- Molecular Structure: Glycyl-L-histidyl-L-lysine
About GHK-Cu
GHK-Cu is a tripeptide (Gly-His-Lys) complexed with bioavailable copper that acts as a tissue-remodeling signaling peptide. Endogenously produced in plasma, serum, and saliva, GHK-Cu plays roles in wound healing, collagen synthesis, and anti-inflammatory signaling. As of February 2026, GHK-Cu was reclassified from FDA Category 2 to Category 1, enabling compounding pharmacy production under physician prescription. Clinical evidence includes studies on skin collagen synthesis, wound closure acceleration, and anti-scarring effects in topical application. Systemic GHK-Cu administration (subcutaneous, intranasal) is being explored for systemic collagen remodeling in fibrotic diseases and aging-related tissue senescence. The copper complex is essential for activity — copper coordinates the peptide's zinc-metalloprotease inhibitory and collagen-stimulating functions. Oral bioavailability is limited; parenteral routes (intranasal, subcutaneous) are typical. Topical application at cosmetic-grade concentrations (1–3 ppm) is established. As of 2026, multiple Phase 1/2 trials for systemic GHK-Cu in fibrotic lung disease and burn wound healing are enrolling. Reclassification permits institutional research and compounding for licensed clinical use.
Clinical Focus
Collagen & Aesthetic Health
Archival Aliases
Copper Peptide, GHK Copper
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
How does GHK-Cu influence collagen synthesis in aged fibroblasts?
GHK-Cu (Copper Tripeptide-1) resets the gene expression of aged human fibroblasts to a healthier state. It upregulates the production of decorin and collagen type I while suppressing the breakdown of the extracellular matrix by matrix metalloproteinases (MMPs), effectively reversing cellular aging markers in skin models.
What is GHK-Cu and where does it naturally occur?
GHK-Cu (Glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper complex found in human plasma, saliva, and urine. Plasma concentrations are highest in young adults at around 200 ng/mL and decline significantly with age, which researchers correlate with reduced wound healing capacity and skin regeneration in older populations.
How does GHK-Cu stimulate collagen production?
GHK-Cu upregulates the synthesis of collagen I, III, and VI by fibroblasts while simultaneously stimulating the production of decorin, a proteoglycan that regulates collagen fiber organization. It also modulates the activity of matrix metalloproteinases (MMPs), enzymes that break down aged collagen, by increasing tissue inhibitors of MMPs (TIMPs).
What is the difference between topical and injectable GHK-Cu?
Topical GHK-Cu (found in skincare serums at 1-5%) acts locally on the dermis, stimulating fibroblast activity and improving skin texture. Its absorption is limited to surface layers. Injectable forms bypass this barrier and allow systemic distribution, which is why they are classified as research-only compounds outside of cosmetic applications. Injectable use has no established clinical dosing protocols for humans.
What are the anti-inflammatory mechanisms of GHK-Cu?
GHK-Cu exerts anti-inflammatory effects through multiple pathways: it suppresses TGF-beta-1 mediated fibrosis, downregulates pro-inflammatory genes (IL-6, TNF-alpha), and activates antioxidant systems including superoxide dismutase and catalase. Studies also show it can reset gene expression of inflammatory genes in damaged tissues toward a healthier baseline.
Does GHK-Cu promote hair growth?
Several studies have found that GHK-Cu stimulates hair follicle enlargement and extends the anagen (growth) phase of the hair cycle. It achieves this by increasing the expression of vascular endothelial growth factor (VEGF) in follicular cells, improving follicle blood supply, and activating hair follicle stem cells. Results in human observational data suggest measurable improvements in hair density at 5% topical concentrations.
What is the research evidence for GHK-Cu in wound healing?
GHK-Cu has a strong preclinical evidence base for wound healing. Studies demonstrate accelerated re-epithelialization, increased angiogenesis at wound sites, and enhanced keratinocyte migration. It has been used in topical wound care products and has shown effectiveness in chronic wound models. Systemic injection studies in animals show accelerated healing of full-thickness wounds.
Can GHK-Cu affect gene expression broadly?
Remarkably, yes. A 2012 gene analysis identified that GHK modulates the expression of over 4,000 human genes — approximately 31% of the genes on the genome array studied. It appears to reset gene expression patterns in aging cells toward a more youthful profile, particularly affecting genes related to inflammation, oxidative stress, and tissue remodeling. This broad genomic influence makes it an active target in longevity research.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | Glycyl-L-histidyl-L-lysine |
| Primary Pathway | Skin & Hair Health |
| Research Phase | FDA Category 1 |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-07